Isomorphic Labs raises $5B Series C to move AI-designed drugs toward clinical trials
The DeepMind spinout did not disclose its valuation, though Bloomberg reported it was seeking funding at a $50 billion valuation.
What happened
Isomorphic Labs is a company that uses AI to design new medicines. It spun out of Google's DeepMind in 2021. It has now raised $5 billion from investors to start testing its drug candidates in human clinical trials.
Why it matters to you
Drug discovery is slow and costly. If AI-designed drugs reach patients, new treatments could arrive sooner, and drug companies are already signing deals with the lab.
The takeaway
A very large investment is backing the bet that AI can help design real medicines.
What it means for you
The engine combines multiple simulation models across chemistry, extending the approach behind AlphaFold into drug design.
Pharma firms such as Eli Lilly, Novartis and Johnson & Johnson already have deals with the lab, so AI drug design is entering partnerships.
The $5 billion Series C came months after a $2.1 billion Series B, and all existing backers joined, though the valuation was not disclosed.